BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.
The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.
Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a "Buy" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。